In short
- The joint research agreement with KYORIN Pharmaceutical Co.,Ltd. is part of a growth strategy to enhance business value through collaboration with external partners.
- The development policy for PPMX-T004 remains unchanged, and master cell bank manufacturing is planned to begin in January 2027.
- Financing through the 29th stock acquisition rights was completed at approximately ¥700 million, compared with the planned approximately ¥930 million, and the ¥150 million development cost for PPMX-T004 is scheduled to be incurred going forward.
What they reported
this period against the same period a year earlier, and where they now expect the year to endSales
| Period | ¥m |
|---|---|
| FY25 Q1 | 20.0 |
| FY25 Q2 | 39.0 |
| FY25 Q3 | 24.0 |
| FY25 Q4 | 37.0 |
| FY26 Q1 | 23.0 |
| FY26 Q2 | 37.0 |
| FY26 Q3 | 43.0 |
| FY26 Q4 | 32.0 |
| FY27 Q1 | 35.0 |
| FY27 Q2 | 17.0 |
Operating profit
| Period | ¥m |
|---|---|
| FY25 Q1 | -221.0 |
| FY25 Q2 | -193.0 |
| FY25 Q3 | -216.0 |
| FY25 Q4 | -196.0 |
| FY26 Q1 | -218.0 |
| FY26 Q2 | -181.0 |
| FY26 Q3 | -174.0 |
| FY26 Q4 | -171.0 |
| FY27 Q1 | -204.0 |
| FY27 Q2 | -207.0 |
Ordinary profit
| Period | ¥m |
|---|---|
| FY25 Q1 | -214.0 |
| FY25 Q2 | -213.0 |
| FY25 Q3 | -197.0 |
| FY25 Q4 | -205.0 |
| FY26 Q1 | -171.0 |
| FY26 Q2 | -174.0 |
| FY26 Q3 | -164.0 |
| FY26 Q4 | -169.0 |
| FY27 Q1 | -201.0 |
| FY27 Q2 | -193.0 |
Net profit
| Period | ¥m |
|---|---|
| FY25 Q1 | -219.0 |
| FY25 Q2 | -276.0 |
| FY25 Q3 | -199.0 |
| FY25 Q4 | -210.0 |
| FY26 Q1 | -176.0 |
| FY26 Q2 | -203.0 |
| FY26 Q3 | -168.0 |
| FY26 Q4 | -171.0 |
| FY27 Q1 | -202.0 |
| FY27 Q2 | -197.0 |
Everything else in the deck
New initiatives
- The company has entered into a joint research agreement with KYORIN Pharmaceutical Co.,Ltd. and will pursue business expansion through collaboration with external partners.
- For PPMX-T004, the company will begin master cell bank manufacturing in January 2027.
What decks usually leave out
COMPUTED = worked out by Komori from reported numbers; the rest are stated in this deckMargins and overheads
Financial targets
| Period | % |
|---|---|
| FY23 | -28.3 |
| FY24 | -58.2 |
| FY25 | -63.9 |
| FY26 | -54.2 |
| Period | % |
|---|---|
| FY22 | 95.5 |
| FY23 | 92.1 |
| FY24 | 78.2 |
| FY25 | 74.4 |
| FY26 | 70.1 |
| FY27 | 62.7 |
Yearly figures are computed by Komori from J-Quants results data (ROE = net profit ÷ average equity). The last point is this year's forecast or latest figure. Targets show only when this deck states them.
Investor Q&A
What was the background to the joint research agreements with KYORIN Pharmaceutical Co.,Ltd., ASKA Pharmaceutical Co., Ltd., and Eurus Therapeutics, and what are the prospects for their development?
The company positions expansion through collaboration as one of its growth strategies and aims to maximize business value by combining its technologies and drug discovery platform with collaboration and alliances involving external partners.
Has the policy of beginning master cell bank manufacturing in January 2027 remained unchanged following the preliminary toxicity studies?
There has been no change to the development policy, and manufacturing is planned to begin in January 2027 as scheduled.
How have the proceeds from past financings been used, and what are the prospects for future financing?
Approximately ¥700 million was raised against the plan for approximately ¥930 million, and the ¥150 million development cost for PPMX-T004 will be spent going forward. There is nothing the company can explain at this time regarding future financing.
What impact will the presentation of the clinical research results at ASH have on licensing-out activities for PPMX-T003?
The presentation provides supplementary information to the Phase I trial data, but the impact on licensing-out activities will be determined by the companies considering in-licensing the product.
What is the expected future impact of PTX3 approval on financial performance?
The company cannot respond because it has not disclosed the details of the joint research agreement.
What is the progress of the licensing-out negotiations, whether there are any expressions of interest, the possibility of conducting the next clinical trial in-house, and the reasons the negotiations are taking time?
The company is exchanging technical information with several interested companies and believes that PPMX-T003 offers product advantages and addresses medical needs.
What is the company's future management policy in light of the review of the continued listing criteria?
The company will research developments at other companies and in the industry, consider various measures, and seek to meet the criteria by increasing corporate value.
How straight each answer was: a number or commitment = straight; a direction without a number = hedged; no answer = dodged.